UCLA Health researchers unveil major advances in breast cancer AI pathology, liquid biopsy, and biomarker strategies at the 2025 SABCS.
Key Details
- 12025 San Antonio Breast Cancer Symposium features UCLA-led research in early detection, precision medicine, and artificial intelligence.
- 2A study of 2,200+ breast cancer cases showed an AI tool (Ataraxis Breast) surpassed current criteria in identifying high-risk HR+/HER2– patients for CDK4/6 therapy.
- 3Research using liquid biopsy (ctDNA) found negative results were linked to less anxiety and greater well-being in survivors.
- 4Simple immune blood markers before treatment predicted pathologic response to neoadjuvant immunotherapy in triple-negative breast cancer.
- 5AI-driven pathology may refine treatment selection, and liquid biopsies show promise in both outcomes tracking and patient support.
Why It Matters
These advances suggest AI and blood-based diagnostics may dramatically improve risk stratification, treatment selection, and quality of life in breast cancer care. The findings point to imminent shifts in clinical workflows and highlight the growing role of artificial intelligence in precision oncology.
Source
EurekAlert
Related News
•EurekAlert
AI Reveals Key Health System Levers for Cancer Outcomes Globally
AI-based analysis identifies the most impactful policy and resource factors for improving cancer survival across 185 countries.
•EurekAlert
Dual-Branch Graph Attention Network Predicts ECT Success in Teen Depression
Researchers developed a dual-branch graph attention network that uses structural and functional MRI data to accurately predict individual responses to electroconvulsive therapy in adolescents with major depressive disorder.
•EurekAlert
Deep Learning Boosts ICD-11 Coding Accuracy for Chinese EMRs
Researchers developed a deep learning model achieving high accuracy in automatic ICD-11 coding of Chinese electronic medical records.